About Arami mohamed

This author has not yet filled in any details.
So far Arami mohamed has created 8 blog entries.

Comp Chem Paper of the Month – March 2026

2026-03-31T14:11:50+00:00

The Open Molecular Software Foundation (OMSF) and the Growing Role of Open Source Software in Molecular Modeling Reading this perspective is a humbling reminder that decades of progress in computational chemistry and molecular modelling has been underpinned by collaboration and permissive open source software licences. The authors present The Open Molecular Software Foundation (OMSF) as

Comp Chem Paper of the Month – March 20262026-03-31T14:11:50+00:00

Med Chem Paper of the Month – March 2026

2026-03-31T14:13:30+00:00

The Affinity Advantage J. Med. Chem. 2026, 69, 3, 1963–1969   To start with, any Med Chem paper written by Mark Murcko is probably worth a read because as one of the key contributors to American medicinal chemistry over the last four decades, it’s worth listening to his experience. In this paper Mark argues¹ for

Med Chem Paper of the Month – March 20262026-03-31T14:13:30+00:00

Med Chem Paper of the Month – February 2026

2026-02-19T16:43:57+00:00

Do Amino-Oxetanes Resemble Amides? A Matched Molecular Pairs Property and Structural Comparison J. Med. Chem. ASAP Oxetanes have long been used in medicinal chemistry campaigns, yet have remained a controversial choice in design due to the lack of this chemotype amongst marketed drugs, until now. This controversy has largely been settled, thanks to the

Med Chem Paper of the Month – February 20262026-02-19T16:43:57+00:00

Comp. Chem Paper of the Month – Feb 2026

2026-02-16T12:12:11+00:00

ActivityFinder: Toward the Fully Automatic Integration of Structural and Binding Affinity Data As the drug discovery industry moves towards using AI models to predict protein-ligand complexes and compound activities, there has never been a greater need for robust and automated curation of structural datasets. Public databases, such as the Protein Data Bank (https://www.rcsb.org/) for protein

Comp. Chem Paper of the Month – Feb 20262026-02-16T12:12:11+00:00

MedChemica joins global research effort addressing antimicrobial resistance

2026-01-26T14:50:13+00:00

Macclesfield, UK – 26 January 2026 – MedChemica is part of a new global initiative, funded by the Gates Foundation, Novo Nordisk, and Wellcome, aimed at combating antimicrobial resistance (AMR) driven by a specific group of bacteria responsible for the majority of AMR-related deaths. The Gram-negative Antibiotic Discovery Innovator (Gr-ADI) focuses on data-sharing and

MedChemica joins global research effort addressing antimicrobial resistance2026-01-26T14:50:13+00:00

Med Chem Paper of the Month – Dec 2025

2025-12-09T09:35:31+00:00

Design, modular synthesis and screening of 58 shape-diverse 3-D fragments     Fragment screening is a tried and tested method of finding quality hit matter for the target of interest, fragment-based drug discovery (FBDD) is thus widely adopted in both academic and industrial settings where ligand-target co-crystal or Cryo-EM structures can be obtained. For

Med Chem Paper of the Month – Dec 20252025-12-09T09:35:31+00:00

Comp. Chem. Paper of the Month – Dec 2025

2025-12-04T11:08:32+00:00

Practically Significant Method Comparison Protocols for Machine Learning in Small Molecule Drug Discovery This open access hands-on perspective offers best-practice recommendations for rigorous method comparison in the domain of ML-based small-molecule property prediction. Given the burgeoning nature of the subject matter, the authors fulfil a contemporary community need in provisioning, by example, a state-of-the-art

Comp. Chem. Paper of the Month – Dec 20252025-12-04T11:08:32+00:00

Finding the right IP strategy for drug discovery and pandemic preparedness – November 2025

2026-04-02T10:34:16+00:00

Every drug hunting project needs its own IP strategy but the current purely market-driven approaches to drug discovery and development alone are insufficient to drive equitable access to new therapies either in preparation for, or in response to, pandemics. Following the experiences gained from the COVID Moonshot program and the ASAP AViDD drug discovery

Finding the right IP strategy for drug discovery and pandemic preparedness – November 20252026-04-02T10:34:16+00:00
Go to Top